Avant Brands Reports Q3 2026 Results Highlighted by Positive Net Income and 51% Growth in Recreational Revenue
Net income of $0.2 million, compared to a net loss of $1.9 million in Q3 2025Adjusted EBITDA¹ of $1.3 million,...
Net income of $0.2 million, compared to a net loss of $1.9 million in Q3 2025Adjusted EBITDA¹ of $1.3 million,...
New AI capability lets patients ask questions about their own medical history in everyday language and receive answers based on...
Will lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovationBrings...
Social Commerce Brands to purchase a minimum US$1 million of Promino products in Q4 2026 and each quarter of 2027...
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal Publication in Molecular Therapy Oncology reports...
EXIT-CVD Consortium Partners EXIT-CVD Consortium Partners Philips Spectral CT in use with patient Philips Spectral CT in use with patient...
MTX325 is a first-in-class, highly potent, orally bioavailable, brain-penetrant USP30 inhibitor designed to modify the course of Parkinson’s by improving...
Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early...
Funding from the Gates Foundation supports development of open-access AI models, workflows and datasets to help researchers identify new tuberculosis...
Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and...
Nantes, France, October 15, 2026 – 7:30am CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company...
October 15, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it...
IBA is preferred supplier for a 12-system national PET radiopharmaceutical production network, securing capacity ahead of demand across diagnostics and...
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases 2026 annual guidanceThe company reports...
Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 millionExpected quarter-over-quarter growth of approximately 11% to 14%...
With autonomous no global treaty in sight, EC-Council will assist any public authority that asks to map ADG 2.0's 180+...
Updated data show stem cell viability is preserved through cryopreservation and 100% engraftment in evaluable transplant recipientsSAN FRANCISCO, Oct. 14,...
REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will...
BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly...